New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:22 EDTIDIX, AZN, CGIX, ALNY, NSR, TSN, HSH, ADI, HITT, DG, FDO, MRK, ACHN, ODPOn The Fly: Pre-market Movers
HIGHER: Idenix (IDIX), up more than 230% after Merck (MRK) acquires the company for $24.50 per share in cash of $3.85B. Idenix peer Achillion (ACHN) is up 35% after Merck's purchase... Hittite Microwave (HITT), up 29% after Analog Devices (ADI) agrees to acquire the company for $78 per share in cash... Family Dollar (FDO), up 11.6% following upgrade at Jefferies after Carl Icahn reported a 9.4% stake in the company. Dollar General (DG), which is being seen as potentially urged as a merger target for Family Dollar based on Icahn's stake, is up 8.6% after the news... Hillshire Brands (HSH), up 4.7% after Tyson Foods (TSN) submits unilaterally binding offer to acquire the company for $8.55B... Office Depot (ODP), up 4.6% after Barron's says shares could jump over 50%... Cancer Genetics (CGIX), up 6.4% after announcing partnership with AstraZeneca (AZN). LOWER: NeuStar (NSR), down 6.3% after calling FCC posting of confidential email "troubling"... Alnylam (ALNY), down 5.8% after presenting ALN-CC5 new pre-clinical data.
News For IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP From The Last 14 Days
Check below for free stories on IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 21, 2014
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
05:35 EDTDG, FDODollar General sends letter to Family Dollar board
Subscribe for More Information
August 20, 2014
17:29 EDTACHNRA Capital reduces stake in Achillion to 21.1% from 23.2%
Subscribe for More Information
11:42 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
August 19, 2014
18:19 EDTTSN, HSHTyson, Hillshire announce extension of tender offer for shares of Hillshire
Subscribe for More Information
16:07 EDTACHNAchillion granted U.S. patent for ACH-3102, structurally related NS5A inhibitors
Subscribe for More Information
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
14:13 EDTDGDollar General upgraded to Outperform from Peer Perform at Wolfe Research
12:18 EDTFDO, DGDollar General could have bought Family Dollar last year, CNBC reports
Subscribe for More Information
12:16 EDTFDO, DGFamily Dollar board frustrated with Dollar General tactics, CNBC reports
Subscribe for More Information
11:41 EDTFDO, DGIcahn says Family Dollar throwing away $300M in fees, Reuters says
Subscribe for More Information
10:42 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
10:13 EDTFDOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:46 EDTFDO, DGFamily Dollar board likely to meet this week, CNBC's Faber reports
Family Dollar's (FDO) board is likely to meet this week to discuss the takeover bid by Dollar General (DG), CNBC's David Faber reports, citing people close to the matter. The board has long focused on antitrust implications and is likely to reject the Dollar General proposal, Faber added. Dollar Tree (DLTR) and Family Dollar previously announced a merger agreement.
09:43 EDTDG, FDOFamily Dollar board likely to reject Dollar General bid, CNBC's Faber reports
Subscribe for More Information
07:29 EDTFDO, DGDollar Tree may raise bid for Family Dollar, says RBC Capital
RBC Capital thinks that Dollar Tree (DLTR) could increase its bid for Family Dollar (FDO) given the revenue and gross margin synergies that the firm thinks the deal would generate. However, the firm believes that Dollar General (DG) would ultimately win a bidding war for Family Dollar, leading to wins for the shareholders of Dollar General and Family Dollar.
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:52 EDTFDOFamily Dollar upgraded to Equal Weight from Underweight at Barclays
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use